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SARS-CoV-2 is a novel coronavirus first identified in December 2019. Notable features make 22 
SARS-CoV-2 distinct from most other previously-identified Betacoronaviruses, including the receptor 23 
binding domain of SARS-CoV-2 and a unique insertion of twelve nucleotide or four amino acids 24 
(PRRA) at the S1/S2 boundary. In this study, we identified two deletion variants of SARS-CoV-2 that 25 
either directly affect the polybasic cleavage site itself (NSPRRAR) or a flanking sequence (QTQTN). 26 
These deletions were verified by multiple sequencing methods. In vitro results showed that the deletion 27 
of NSPRRAR likely does not affect virus replication in Vero and Vero-E6 cells, however the deletion 28 
of QTQTN may restrict late phase viral replication. The deletion of QTQTN was detected in 3 of 68 29 
clinical samples and half of 24 in vitro isolated viruses, whilst the deletion of NSPRRAR was identified 30 
in 3 in vitro isolated viruses. Our data indicate that (i) there may be distinct selection pressures on 31 
SARS-CoV-2 replication or infection in vitro and in vivo, (ii) an efficient mechanism for deleting this 32 
region from the viral genome may exist, given that the deletion variant is commonly detected after two 33 
rounds of cell passage, and (iii) the PRRA insertion, which is unique to SARS-CoV-2, is not fixed 34 
during virus replication in vitro. These findings provide information to aid further investigation of 35 
SARS-CoV-2 infection mechanisms and a better understanding of the NSPRRAR deletion variant 36 
observed here. 37 
 38 
Important notes 39 
The spike protein determines the infectivity and host range of coronaviruses. SARS-CoV-2 has two 40 
unique features in its spike protein, the receptor binding domain and an insertion of twelve nucleotides 41 
at the S1/S2 boundary resulting a furin-like cleavage site. Here, we identified two deletion variants of 42 
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SARS-CoV-2 that either directly affect the furin-like cleavage site itself (NSPRRAR) or a flanking 43 
sequence (QTQTN) and investigated these deletions in cell isolates and clinical samples. The absence 44 
of the polybasic cleavage site in SARS-CoV-2 did not affect virus replication in Vero or Vero-E6 cells. 45 
Our data indicate the PRRAR and its flanking sites are not fixed in vitro, thus there appears to be 46 
distinct selection pressures on SARS-CoV-2 sequences in vitro and in vivo. Further investigation of the 47 
mechanism of generating these deletion variants and their infectivity in different animal models would 48 
improve our understanding of the origin and evolution of this virus. 49 
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SARS-CoV-2 is a novel coronavirus that was first identified at the end of December 2019 (1) and 52 
responsible for the global pandemic of COVID-19(2). Unlike the two other zoonotic coronaviruses, 53 
SARS-CoV-1 and MERS-CoV(3), the evolutionary history of SARS-CoV-2 is largely unknown. A 54 
recent analysis of genetic information and the spike (S) protein structure(4, 5) highlights two notable 55 
features of the SARS-CoV-2 genome. First, the receptor binding domain (RBD) of SARS-CoV-2 is 56 
distinct from the most closely-related virus (RaTG13) of bat origin and more closely related to 57 
pangolin coronaviruses(6, 7). The spike protein of SARS-CoV-2 is demonstrated to have a high affinity 58 
for the human ACE2 receptor molecule(4). Second, a unique insertion of 12 nucleotides (encoding four 59 
amino acids, PRRA) at the S1/S2 boundary(8) leading to a predictively solvent-exposed PRRAR|SV 60 
sequence, which corresponds to a canonical furin-like cleavage site(9, 10).  61 
 62 
With respect to the first feature, an RBD identified in a SARS-like virus from a pangolin suggests that 63 
an RBD similar to that of SARS-CoV-2 may already exist in mammalian host(s) prior to its 64 
introduction into humans(7). The question remaining is the history and function of the insertion at the 65 
S1/S2 boundary, which is unique to SARS-CoV-2. By sequencing the whole genome of SARS-CoV-2 66 
from cell isolates and clinical samples, we identified two deletion variants that directly affect the furin 67 
cleavage site itself (NSPRRAR) or a flanking sequence (QTQTN). We screen these two deletions in 68 
cell-isolated strains and clinical samples. To explore the potential effect of these deletions, these two 69 
deletion variants were isolated and their replication kinetics were investigated in both Vero and 70 
Vero-E6 cells.  71 
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Identification of deletions in SARS-CoV-2 spike protein 73 
The first COVID-19 clinical case (Sample 014, Table1) in Guangdong was reported on 19th January, 74 
with illness onset on 1st January(11). A BALF (bronchoalveolar lavage fluid) sample from this patient 75 
was collected and inoculated on Vero-E6 cells. A cell-isolated viral strain was obtained after three 76 
rounds of passage. Multiple sequencing methods were used for whole genome sequencing and the 77 
validation of variants (Figure1 A, Table1), including multiplex-PCR with Miseq platform (PE150), 78 
direct CDNA sequencing in Nanopore platform and Sanger sequencing (See Materials and Methods for 79 
detail). After mapping to the SARS-CoV-2 reference genome (MN908947.3), we found that there were 80 
two variants in the cell-isolated viral strain with deletions at (1) 23585–23599 (Var1), flanking the 81 
polybasic cleavage site, resulting in a QTQTN deletion in the spike protein (one amino acid before the 82 
polybasic cleavage site) and (2) 23597–23617 (Var2), resulting in a NSPRRAR deletion that includes 83 
the polybasic cleavage site (Figure 1A). To exclude the possibility that these findings were caused by 84 
errors in PCR amplification, both of the deletion variants were verified through direct cDNA 85 
sequencing on the ONT nanopore platform. Sanger sequencing with specific primers also identified 86 
heterozygous peaks with distinct double peaks starting at the position 23585 and triple peaks after that, 87 
highlighting the existence of multiple variants caused by the above two deletions (Figure 1B). To 88 
investigate the dynamics of these deletion variants, we performed nanopore sequencing on the 014 89 
viral strain, isolated at different rounds of passage from the Vero-E6 cell culture (Figure 1C). High 90 
frequencies of the deletion variant Var1were observed after the first passage and high frequencies of the 91 
deletion variant Var2 were observed after the 4th passage, at which point the frequency of Var1 and 92 
Var2 reached around 50%. The percentages of these two deletion variants were steady in the following 93 
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passages.   94 
 95 
The deletion is commonly identified in cell isolated strains 96 
To investigate whether the deletions described above were random mutations that occasionally arise in 97 
a strain, or whether they commonly occur after cell passages, we performed whole genome sequencing 98 
on 23 other SARS-CoV-2 strains collected after two rounds of cell passage in Vero-E6 or Vero cells 99 
(Table 1). The corresponding original samples for these strains were collected between 19th January and 100 
28th February 2020. In addition to the 014 strain mentioned above, 10 out of 18 Vero-E6 isolated strains 101 
and 1 out of 5 Vero isolated strains displayed the Var1 deletion variant (>10% of sequencing reads; 102 
Figure 1D). Additionally, in two Vero-E6 isolated strains (619 and 4276), Var2 was detected, and this 103 
variant has been independently identified by another group almost at the same time, using direct RNA 104 
sequencing method(12). To find out whether these deletions were restricted to a specific genetic lineage, 105 
we next investigated the phylogenetic relationship of these viral strains. As shown in Figure 1D, the 106 
strains with a relatively higher ratio of this deletion were dispersed in the phylogenetic tree, that 107 
suggesting the deletion mutations did not arise through shared ancestry and were not restricted to a 108 
specific genetic lineage of SARS-CoV-2 viruses.  109 
 110 
Replication kinetics of the deletion variants 111 
To evaluate the effect of these deletions on virus replication, we performed plaque assays and picked 112 
individual clones for different variants. Single plaques for Var1 and Var2 were obtained and confirmed 113 
by whole genome sequencing (014-Var1, 014-Var2; Table 1). However, the 014 strain without these 114 
deletions could not be successfully selected from plaques, possibly due to the replication advantage of 115 
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the deletion variants in cell culture. We investigated the replication kinetics of 014-Var1 and 014-Var2 116 
in Vero-E6 and Vero cells. The strain 029/E6 was used as a reference, which has no deletion mutations 117 
and only one amino acid difference from strain 014 on the spike protein (H47Y). The viral replication 118 
kinetics were assessed by detecting the intracellular viral loads at 1, 3, 6, 9, 12 and 24 hours post 119 
inoculation (Figure 2). As shown in Figure 2A, the 014-Var1 and 014-Var2 exhibit similar replication 120 
dynamics to the 029 strain in Vero-E6 cells. In contrast, the deletion of 23583–23599 in SARS-CoV-2 121 
(Var1) significantly diminishes cellular viral load at 24 hours post-inoculation in Vero cells (Figure 2B) 122 
and to a lesser extent in Vero-E6 cells (Figure 2A). This is the possible reason that 014-Var1 was 123 
observed less often in Vero cells than in Vero-E6 cells (Figure 1D).    124 
 125 
Screening for deletion variants in original clinical samples 126 
To identify whether these deletions also occurred in the original clinical samples, we screened 127 
high-throughput sequencing data from 149 clinical samples, which were collected between 6th February 128 
and 20th March in Guangdong, China. There were 68 SARS-CoV-2 genomes, with an average 129 
sequencing depth ≥20 at the sites neighboring 23585. As shown in Table 2, variants with the QTQTN 130 
(Var1) were found in 3 (4%) of clinical samples, with the ratio of deletion variant in total reads ranging 131 
from 8.8–32.8%, indicating that this deletion also occurs in in vivo infections. Notably, two out of the 132 
three patients from which these samples were derived displayed mild symptoms and recurrence of 133 
SARS-CoV-2 infection after being discharged from hospital. The sequenced samples were collected at 134 
4 days and 17 days after discharge, respectively. The third case (20SF5645) was an asymptomatic 135 
infection case. To date, there are no genome sequences deposited in public databases containing these 136 
two deletions. While the described Var1 deletion variant was only detected in clinical samples after 137 
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deep sequencing, such variants may be underrepresented in databases due to the low frequency and 138 
consequent elimination upon consensus sequence generation. 139 
 140 
Discussion 141 
The spike protein of coronaviruses plays an important role in viral infectivity, transmissibility and 142 
antigenicity. Therefore, the genetic character of the spike protein in SARS-CoV-2 may shed light on its 143 
origin and evolution(7, 8). For SARS-CoV-1, positive selection was identified in the spike coding 144 
sequence(13) and deletions in ORF8(14) during the early, but not late, stage of the epidemic, 145 
suggesting that SARS-CoV-1 may have been sub-optimal in the human population during the early 146 
epidemic stage after it was first transmitted from an intermediate animal host, and underwent further 147 
adaptation. SARS-CoV-2, however, has presented high infectivity and efficient transmission capability 148 
since its identification(1) suggesting the polybasic cleavage site is an important component of the virus’ 149 
fitness within the human population. Genetic changes related to viral fitness of SARS-CoV-2 require 150 
further epidemiological investigation and functional analysis. 151 
 152 
Here, we use different sequencing methods to identify and verify two deletion variants either directly 153 
affecting the polybasic cleavage site (Var1) or a site immediately upstream of it (Var2). The QTQTN 154 
deletion variant (Var1) was detected in 3 out of 68 clinical samples and half of the 24 in vitro isolated 155 
viral strains tested in this study. The cellular replication kinetic data suggests the deletion of the 156 
polybasic cleavage site does not affect SARS-CoV-2 replication in Vero and Vero-E6 cells, whilst the 157 
QTQTN deletion may restrict virus replication in Vero cells at the late phase. These data indicate that (i) 158 
the deletions of QTQTN and the polybasic cleavage site are likely under strong purifying selection in 159 
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vivo, since the deletion is rarely identified in clinical samples, (ii) there may be an efficient mechanism 160 
for generating these deletions, given that the QTQTN deletion (Var1) is commonly detected after two 161 
rounds of cell passage and (iii) the PRRA insertion, which distinguishes SARS-CoV-2 from other 162 
SARS-like viruses, is not fixed in vitro, because the NSPRRAR deletion variant (Var2) is observed in 3 163 
out of 24 Vero-E6 isolated strains, but does appear to be subject to purifying selection in vivo. 164 
 165 
Given that these residues are located in solvent-accessible loops of the spike protein, combined with 166 
the observation that they are either partially (QTQTN) or completely (NSPRRAR) unresolved in 167 
recently reported SARS-CoV-2 S cryoEM structures(4, 5) (Figure 3), it seems likely that this region is 168 
structurally tolerant to deletions. Whilst the deletion of the furin site, as observed in Var2, would result 169 
in a loss of susceptibility to furin cleavage at this site, the effect of Var1 on furin cleavage is less 170 
evident. However, it is likely that these overlapping deletion variants have arisen through the same 171 
selective pressure and are therefore both likely to compromise furin-mediated cleavage at this position 172 
in the S protein, albeit possibly to different extents. Furthermore, it is possible that the presence of a 173 
conserved cathepsin L site 10 residues downstream of the polybasic cleavage site may provide 174 
functional tolerance(15) to any reduction in proteolytic cleavage efficiency that may arise from changes 175 
in this region (Figure 1A). Consistent with the modeling analysis, the replication dynamics in Vero and 176 
Vero-E6 cells also indicate that polybasic cleavage site deletion (Var2) does not affect virus replication 177 
in vitro. 178 
 179 
Notably, a recently reported SARS-like strain, RmYN02, which is phylogenetically related to 180 
SARS-CoV-2, also has a possible deletion at the QTQT site(16). This raises another possible scenario, 181 
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which is that some SARS-CoV-2-like viruses in animals may not have had QTQTN in their spike 182 
protein. The origin of polybasic cleavage site (PRRA) is important to understanding the evolution 183 
history and tracing the potential animal reservoir(s) of SARS-CoV-2. Here, the different deletion 184 
frequencies observed in vitro and in vivo have provide clues that will aid further investigation of this 185 
evolutionary tale. The absence of NSPRRA in isolated SARS-CoV-2 strains could be used to further 186 
investigate its infectivity in different potential intermediate animal hosts and resolve the origin of this 187 
feature of the SARS-CoV-2 genome. In addition, the different selective pressure observed on NSPRRA 188 
region of SARS-CoV-2 in vivo and in vitro highlight the NSPRRA deletion variant generated in this 189 
study as a promising vaccine candidate in the future.  190 
  191 
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Materials and Methods  192 
Ethics 193 
This study was approved by ethics committee of the Center for Disease Control and Prevention of 194 
Guangdong Province. Written consent was obtained from patients or their guardian(s) when clinical 195 
samples were collected. Patients were informed about the surveillance before providing written consent, 196 
and sequence data were analyzed anonymously. 197 
 198 
Viral isolation 199 
Vero E6 or Vero cells were used for SARS-CoV-2 virus isolation and passage. The cells were inoculated 200 
with 100 µl processed patient sample. Cytopathic effect (CPE) were observed daily. If there was no CPE 201 
observed, cell lysis was collected by centrifugation after three repeated freeze-thaw and 100 µl 202 
supernatant were used for the second round of passage.  203 
 204 
Genetic sequencing and sequence analysis 205 
The deletion variants of SARS-CoV-2 were confirmed by different approaches as previously 206 
described(17) (i) using version 1 of the ARTIC COVID-19 multiplex PCR primers 207 
(https://artic.network/ncov-2019), followed by sequencing on a Miseq PE150 or an ONT 208 
MinION, (ii) CDNA directly sequencing on an ONT MinION and (iii) sanger sequencing by 209 
using the nCoV-2019_78_LEFT and nCoV-2019_78_RIGTH primers from the ARTIC 210 
COVID-19 multiplex PCR primers set. The amplification products targeting the 23444-23823 211 
fragment of viral genome (numbered according to MN908947.3).  212 
 213 
For metatranscriptomics, total RNAs were extracted from different types of samples by using 214 
QIAamp Viral RNA Mini Kit, followed by DNase treatment and purification with TURBO 215 
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DNase and Agencourt RNAClean XP beads. Libraries were prepared using the SMARTer 216 
Stranded Total RNA-Seq Kit v2 (according to the manufacturer’s protocol starting with 10 ng 217 
total RNA. Sequencing of metatranscriptome libraries was conducted on the Illumina Miseq 218 
PE 150 platform. For the multiplex PCR approach, we followed the general method of 219 
multiplex PCR as described in (https://artic.network/ncov-2019)(18). Briefly, multiplex PCR was 220 
performed with two pooled primer mixtures and cDNA reverse-transcribed with random primers was 221 
used as a template. After 25-35 rounds of amplification, PCR products were collected and quantified, 222 
followed by sequencing on Illumina Miseq PE 150 platform or MinION sequencing device. 223 
Assembly of the Illumina raw data was performed using Geneious v11.0.3 224 
(https://www.geneious.com). Assembly of the nanopore raw data was performed using the ARTIC 225 
bioinformatic pipeline for COVID-19 with minimap2(19) and medaka 226 
(https://github.com/nanoporetech/medaka) for consensus sequence generation. Variant sites were called 227 
by using iVar(20) with depth >=20 as a threshold. For direct cDNA sequencing, we followed the 228 
Nanopore Direct cDNA sequencing protocol (SQK-DCS109). Briefly, 100ng viral RNA were reverse 229 
transcripted using SuperScript™ IV First-Strand Synthesis System (Invitrogen, USA) followed by 230 
RNA chain digestion and second strand synthesis. A total of 20ng cDNA libraries were loaded to 231 
FLO-MIN106 flow cell. Generated sequences were mapped to MN908947.3 reference sequence using 232 
minimap2. The ML phylogeny for 24 viral strains genomes was estimated with PhyML(21) 233 
using the HKY+Ⲅ4 substitution model(22) with gamma-distributed rate variation(23). 234 
 235 
Viral kinetics analysis 236 
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The individual clones of deletion variants were selected by using a plaque assay. The isolated 014 237 
strains were serially-diluted and used to inoculate the monolayer of Vero-E6 cells. When CPE were 238 
observed, the cell monolayers were scraped with the back of a pipette tip. Virus lysate was used for 239 
genetic sequencing and viral strain amplification. To assess the kinetic of virus replication, different 240 
viral strains were first tiltered and inoculated with Vero-E6 and Vero cells at MOI 0.5. Time was set as 241 
zero when cells were incubated with viruses. After 1 hour adsorption, the culture media were removed 242 
and cells were washed twice with PBS to remove unattached virus. Cells were lysed at different time 243 
post inoculation and total RNA was extracted by using RNeasy mini kit (QIAGEN, Germany). Cellular 244 
viral loads were calculated by using SARS-CoV-2 RT-PCR kit (DAAN GENE, Guangzhou, China) and 245 
GAPDH (glyceraldehyde-3-phosphate dehydrogenase) gene was parallelly quantified as an 246 
endogenous control.  247 
 248 
Data Availability 249 
Metagenomic sequencing, multiplex PCR sequencing and cDNA direct sequencing data after mapping 250 
to SARS-COV-2 reference genome (MN908947.3) have been deposited in the Genome Sequence 251 
Archive(24) in BIG Data Center(25), Beijing Institute of Genomics (BIG), Chinese Academy of 252 
Sciences, under project accession numbers CRA002500, publicly accessible at 253 
https://bigd.big.ac.cn/gsa. The sample information and corresponding accession number for each 254 
sample are listed in the Table 1. 255 
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Figure legends 349 
Figure1. Deletion variants identified in SARS-CoV-2 cell strains. (A) High-throughput sequencing 350 
of the cell-isolated strain (014) from the first SARS-CoV-2 patient (EPI 403934) in Guangdong, China. 351 
Representative reads mapping to the SARS-CoV-2 genome (MN908947.3 used as reference genome) 352 
showed two deletion variants. Redundant proteolytic cleavage sites including furin cleavage site 353 
(PRRARS|V) and cathepsin L site (QSIIAY|T) are marked with red arrows (B) Sanger sequencing of 354 
the 014 cell strains. Heterozygous peaks are highlighted with a red box and sites with distinct three 355 
peaks are marked with * (C) Results of high-throughput sequencing, showing the ratio of deletion 356 
variants in original clinical sample SF014 (P0) and in cell strains, after 7 rounds of cell passage (P1-7). 357 
The size of square was proportion to the number of reads having these deletions. (D) Phylogenetic tree 358 
of genome sequences of all 24 SARS-CoV-2 cell strains (see Table 1). The size of the circles is 359 
proportional to the percentage of Var1 (QTQTN deletion at 23585–23599) in total reads, except for 360 
strains 619, 4279 and 014 in which Var2 deletions were detected. The maximum likelihood tree was 361 
rooted with the reference genome MN908947.3.  362 
 363 
Figure 2. The replication kinetics of the deletion variants in Vero-E6 and Vero cells. Vero-E6 and 364 
Vero cells were infected with the isolated strains 014_Var1, 014_Var2, and 029/E6 (Table 1) at 365 
multiplicity of infection (MOI) 0.5. Viral RNA was quantified by real-time PCR using GAPDH as 366 
endogenous control. At the each time point, the relative fold-change in total intracellular viral RNA 367 
was measured by comparison with the viral RNA level at 1-hour post inoculation. Data are the mean ± 368 












Figure3. Observed deletions near the S1/S2 boundary map to a unresolved region in the cryoEM 371 
structure of SARS-CoV-2 S. Cartoon representation of the SARS-CoV-2 S protein ectodomain, as 372 
resolved by Walls and colleagues(4) (PDB: 6VXX). The S1 and S2 subunits of the different protomers 373 
are indicated (white and grey, respectively). The unresolved loop that contains part of deletion Var1 374 
(675QTQTN679) and all of deletion Var2 (679NSPRRAR685) is indicated within each protomer of the 375 
trimeric assembly through signposting flanking residues T676 and S689 as spheres in deep teal. Similarly, 376 
the first residue of Var1 (Q675), which is resolved in the structure, is indicated as an orange surface 377 
within each of the S protomers. N-linked glycans are shown as blue spheres and the Asn side chains to 378 
which the glycans are linked are presented as sticks. Inset: A zoomed-in side view representation of this 379 
local arrangement is shown. T676 and S689, which flank the unresolved loop, and Var1 residue Q675 are 380 
numbered and indicated under transparent spheres as deep teal and orange sticks, respectively. A 381 
dashed line indicating the approximate position of the connecting unresolved loop is shown. N-linked 382 
glycans are presented as in the original image with their residue numbers marked. 383 
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BALF Original 014 Metagenomic SAMC151281 






Vero-E6 Plaque 014_Var1 PCR+Nanopore SAMC192628 
Vero-E6 Plaque 014_Var2 PCR+Nanopore SAMC192629 
Case2 Vero-E6 2 025/E6 PCR+Nanopore SAMC150991 
Case3 
Vero 2 028/Vero PCR+Nanopore SAMC150988 
Vero-E6 2 028/E6 PCR+Nanopore SAMC150992 
Case4 Vero-E6 2 029/E6 PCR+Nanopore SAMC150975 
Case5 
Vero-E6 2 107/E6 PCR+Nanopore SAMC150977 
Vero 2 107/Vero PCR+Nanopore SAMC150989 
Case6 
Vero-E6 2 108/E6 PCR+Nanopore SAMC150993 
Vero 2 108/Vero PCR+Nanopore SAMC150995 
Case7 
Vero-E6 2 112/E6 PCR+Nanopore SAMC150976 
Vero 2 112/Vero PCR+Nanopore SAMC150994 
Case8 
Vero-E6 2 115/E6 PCR+Nanopore SAMC150978 
Vero 2 115/Vero PCR+Nanopore SAMC150990 
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Case9 Vero-E6 2 252/E6 PCR+Nanopore SAMC150980 
Case10 Vero-E6 2 262/E6 PCR+Nanopore SAMC150981 
Case11 Vero-E6 2 263/E6 PCR+Nanopore SAMC150983 
Case12 Vero-E6 2 265/E6 PCR+Nanopore SAMC150982 
Case13 Vero-E6 2 272/E6 PCR+Nanopore SAMC150984 
Case14 Vero-E6 3 619/E6 PCR+Nanopore SAMC153235 
Case15 Vero-E6 2 1676/E6 PCR+Nanopore SAMC150979 
Case16 Vero-E6 3 4276/E6 PCR+Nanopore SAMC153234 
Case17 Vero-E6 2 F2/E6 PCR+Nanopore SAMC150985 
Case18 Vero-E6 2 F4/E6 PCR+Nanopore SAMC150986 
Case19 Vero-E6 2 F5/E6 PCR+Nanopore SAMC150987 
Case20 nasopharyngeal Original 20SF5645 PCR+Nanopore SAMC150972 
Case21 nasopharyngeal Original ST-N3-D PCR+Nanopore SAMC150973 
Case22 nasopharyngeal Original SZ-N16-D PCR+Nanopore SAMC150974 
 386 
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Table 2: QTQTN deletion variant (23585–23599, Var1) identified in clinical samples 388 
Samples Days post 
illness onset 
REF_depth ALT_depth Del Variant Ratio 
20SF5645 Asymptomatic 104 25 19.4% 
ST-N3-D* 16 82 8 8.8% 
SZ-N16-D* 30 256 125 32.8% 
* Cases detected with the recurrence of SARS-CoV-2 after discharge 389 
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